Upcoming Events for SQURPHARMA — DSE

Tue, 10 Nov 2026

SQURPHARMA Board Meeting

LTP 218.50

Details

[Q1] to consider, among others, un-audited financial statements for the first quarter (q1) period ended september 30, 2026 · 3:00 pm

Mon, 16 Nov 2026

SQURPHARMA Record Date

LTP 218.50 At notice 218.80 Impact -0.14%

Details

The Board of Directors has recommended 130% Cash Dividend for the year ended June 30, 2026. Date of AGM: 15.12.2026, Time: 10:00 AM, Venue: Virtual Platform. Record Date: 16.11.2026. The Company has also reported Consolidated EPS of Tk. 31.24, Consolidated NAV per share of Tk. 178.99 and Consolidated NOCFPS of Tk. 18.65 for the year ended June 30, 2026 as against Tk. 27.04, Tk. 157.88 and Tk. 19.52 respectively for the year ended June 30, 2025. (cont.)

Tue, 15 Dec 2026

SQURPHARMA AGM Date

LTP 218.50 At notice 218.80 Impact -0.14%

Details

The Board of Directors has recommended 130% Cash Dividend for the year ended June 30, 2026. Date of AGM: 15.12.2026, Time: 10:00 AM, Venue: Virtual Platform. Record Date: 16.11.2026. The Company has also reported Consolidated EPS of Tk. 31.24, Consolidated NAV per share of Tk. 178.99 and Consolidated NOCFPS of Tk. 18.65 for the year ended June 30, 2026 as against Tk. 27.04, Tk. 157.88 and Tk. 19.52 respectively for the year ended June 30, 2025. (cont.)